Early Pharmacological Treatment of Autism: A Rationale for Developmental Treatment
- 15 February 2007
- journal article
- review article
- Published by Elsevier BV in Biological Psychiatry
- Vol. 61 (4), 521-537
- https://doi.org/10.1016/j.biopsych.2006.09.021
Abstract
No abstract availableThis publication has 264 references indexed in Scilit:
- Gender-Dependent Modulation of Brain Monoamines and Anxiety-like Behaviors in Mice with Genetic Serotonin Transporter and BDNF DeficienciesCellular and Molecular Neurobiology, 2006
- Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEPNeuropharmacology, 2005
- Placebo effects in developmental disabilities: Implications for research and practiceMental Retardation and Developmental Disabilities Research Reviews, 2005
- Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X SyndromeNeuron, 2005
- ‘Nurturing the brain’ as an emerging research field involving child neurologyBrain & Development, 2004
- Serum neurotrophin concentrations in autism and mental retardation: a pilot studyBrain & Development, 2004
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004
- Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid‐compulsive subset of autismNeuropsychiatric Genetics, Part B of the American Journal of Medical Genetics (AJMG), 2003
- Genetic studies in autistic disorder and chromosome 15neurogenetics, 2000
- AutismPediatric Drugs, 2000